Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.50 |
| ▸ | RORC | P51449 | 4/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPRS | Q13332 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5572731 | 0.90 | MAPK1 (0.48) | STAT3RORCMMP9MMP13KDM1A | |
| SCHEMBL30699961 | 0.87 | CA1 (0.54) | MAPK1KMT2ATDP1KDM4ELMNA | |
| SCHEMBL5572753 | 0.87 | SMN1; SMN2 (0.55) | MMP9MAPK1KMT2AKDM4ELMNA | |
| SCHEMBL5573302 | 0.86 | KMT2A (0.47) | MAPK1KMT2ATDP1KDM4ELMNA | |
| SCHEMBL7325748 | 0.85 | MAPK1 (0.46) | MMP9MMP13MAPK1KMT2ATDP1 | |
| SCHEMBL7325742 | 0.85 | MAPK1 (0.46) | MMP9MMP13MAPK1KMT2ATDP1 | |
| SCHEMBL7319084 | 0.84 | TDP1 (0.51) | STAT3MAPK1KMT2ATDP1KDM4E | |
| SCHEMBL5496683 | 0.84 | LMNA (0.61) | MAPK1KMT2ATDP1KDM4ELMNA | |
| SCHEMBL5496678 | 0.84 | LMNA (0.61) | MAPK1KMT2ATDP1KDM4ELMNA | |
| SCHEMBL7316305 | 0.84 | MMP13 (0.48) | MMP9MMP13MAPK1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166580-B2 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-01-23 | — | — | US | claimed |
| US-20030166575-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN MA INC. | 2003-09-04 | — | — | US | claimed |
| EP-1001973-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | claimed |
| WO-1999006433-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | claimed |
| US-7166580-B2 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20030166575-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN MA INC. | 2003-09-04 | — | — | US | disclosed |
| US-6559127-B1 | Intercellular adhesion mediated by VLA-4 and other cell surface receptors is associated with a number of inflammatory responses | ATHENA NEUROSCIENCES, INC. | 2003-05-06 | — | — | US | disclosed |
| EP-1001973-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006433-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166575-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | STAT3 1100/4885RORC 345/4885MMP9 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.